

Application Number: Pending

Docket: 7214.08

***Conclusion***

In view of the foregoing, Applicant submits that all pending claims are allowable. The Examiner is invited to telephone the undersigned attorney for Applicants in the event that such communication is deemed to expedite prosecution of this application.

Respectfully submitted,

DORSEY & WHITNEY LLP

Date: October 19, 2001

By: Scott D. Rothenberger

Scott D. Rothenberger

(Reg. No. 41,277)

DORSEY & WHITNEY LLP

Suite 1500

50 South Sixth Street

Minneapolis, MN 55402-1498

Telephone: (612) 340-8819


Facsimile: (612) 340-8856

1004-3408856


**MARKED-UP VERSION SHOWING CHANGES**

In the specification:


At page 11, lines 5 through 10, please delete




and insert therefore - -



At page 14, lines 1 through 7, please delete




and insert therefore - -




--

At page 17, lines 1 through 7, please delete




and insert therefore - -




--

At page 19, lines 21 through 30, please delete




and insert therefore - -



In the claims:


17. (New) A method for modulating a disease or condition associated with phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated polymorphonutrophil (PMN) inflammation in a subject is modulated.

18. (New) The method of claim 17, wherein said method is performed *in vitro*.
19. (New) The method of claim 17, wherein said method is performed *in vivo*.


20. (New) A method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoneutrophil (PMN) inflammation is treated in a subject.

21. (New) The method of claim 20, wherein said method is performed *in vitro*.
22. (New) The method of claim 20, wherein said method is performed *in vivo*.

23. (New) A method for modulating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula




wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that a disease or condition associated with PLD initiated superoxide generation or degranulation activity in a subject is modulated.

24. (New) The method of claim 23, wherein said method is performed *in vitro*.
25. (New) The method of claim 23, wherein said method is performed *in vivo*.




26. (New) A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.

27. (New) The method of claim 26, wherein said method is performed *in vitro*.
28. (New) The method of claim 26, wherein said method is performed *in vivo*.

29. (New) A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated activity in a subject, comprising:  
a container holding a therapeutically effective amount of at least one lipoxin compound having the formula




wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated activity in the subject.

30. (New) A packaged pharmaceutical composition for treating phospholipase D initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula




wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated activity in the subject.

31. (New) A packaged pharmaceutical composition for treating a disease or condition associated with phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:


a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating a disease or condition associated with PLD initiated superoxide generation or degranulation activity in the subject.

32. (New) A packaged pharmaceutical composition for treating phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:  
a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated superoxide generation or degranulation activity in the subject.